Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Clin Cancer Res. 2010 Mar 23;16(7):2009–2021. doi: 10.1158/1078-0432.CCR-09-2801

Figure 2.

Figure 2

SELENBP1 expression was decreased in samples of high-grade dysplasia (*) and adenocarcinoma (T), when compared with areas of non-dysplastic Barrett's esophagus (arrows) as indicated by IHC analysis using tissue microarray (TMA) of esophageal surgical specimens from 73 patients. Representative sections from TMA for SELENBP1 expression at A, 4×, B and C, 10× magnification. D, Western immunoblotting demonstrated specific binding to SELENBP1 in patient specimens of Barrett's metaplasia (B) and esophageal adenocarcinoma (T). β-actin was used as a loading control.